Pinocembrin Ameliorates Cognitive Impairment Induced by Vascular Dementia: Contribution of Reelin-dab1 Signaling Pathway

Drug Des Devel Ther. 2020 Sep 4:14:3577-3587. doi: 10.2147/DDDT.S249176. eCollection 2020.

Abstract

Background: As a substrate of apoER2, Reelin has been verified to exert neuroprotection by preventing memory impairment. Pinocembrin is the most abundant natural flavonoid found in propolis, and it has been used to exert neuroprotection, blood-brain barrier protection, anti-oxidation, and inflammation diminishing, both in vitro and in vivo. However, the roles and molecular mechanisms of pinocembrin in neurobehavioral outcomes and neuronal repair after vascular dementia are still under investigation.

Purpose: To explore the role of pinocembrin in the involvement of the Reelin-dab1 signaling pathway in improving memory impairment, both in cell culture and animals experiments.

Material and methods: Behavioral tests were conducted on day 48 to confirm the protection of pinocembrin against cognitive impairment. Cell and molecular biology experiments demonstrated that the Reelin-dab1 pathway mediates the underlying mechanism of cognitive improvement by pinocembrin.

Results: It was showed that pinocembrin alleviated learning and memory deficits induced by vascular dementia, by inducing the expression of Reelin, apoER2, and p-dab1 in the hippocampus. The expression of Reelin and p-dab1 was both inhibited following Reelin RNA interference in SH-SY5Y prior to oxygen glucose deprivation (OGD) injury, suggesting that Reelin played a core role in pinocembrin's effect on OGD in vitro.

Conclusion: Pinocembrin improves the cognition via the Reelin-dab1 signaling pathway.

Keywords: Reelin; cognitive impairment; hippocampus; pinocembrin; signaling pathway; vascular dementia.

MeSH terms

  • Adaptor Proteins, Signal Transducing / antagonists & inhibitors
  • Adaptor Proteins, Signal Transducing / genetics
  • Adaptor Proteins, Signal Transducing / metabolism*
  • Animals
  • Behavior, Animal / drug effects
  • Cell Adhesion Molecules, Neuronal / antagonists & inhibitors
  • Cell Adhesion Molecules, Neuronal / genetics
  • Cell Adhesion Molecules, Neuronal / metabolism*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cognitive Dysfunction / drug therapy*
  • Cognitive Dysfunction / metabolism
  • Cognitive Dysfunction / pathology
  • Dementia, Vascular / drug therapy*
  • Dementia, Vascular / metabolism
  • Dementia, Vascular / pathology
  • Dose-Response Relationship, Drug
  • Extracellular Matrix Proteins / antagonists & inhibitors
  • Extracellular Matrix Proteins / genetics
  • Extracellular Matrix Proteins / metabolism*
  • Flavanones / pharmacology*
  • Humans
  • Male
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism*
  • RNA, Small Interfering / pharmacology
  • Rats
  • Rats, Wistar
  • Reelin Protein
  • Serine Endopeptidases / genetics
  • Serine Endopeptidases / metabolism*
  • Signal Transduction / drug effects

Substances

  • Adaptor Proteins, Signal Transducing
  • Cell Adhesion Molecules, Neuronal
  • Dab1 protein, rat
  • Extracellular Matrix Proteins
  • Flavanones
  • Nerve Tissue Proteins
  • RNA, Small Interfering
  • Reelin Protein
  • Reln protein, rat
  • pinocembrin
  • RELN protein, human
  • Serine Endopeptidases

Grants and funding

This work was financially supported by National Science and Technology Major Projects for Major New Drugs Innovation and Development (2013ZX09508104, 2013ZX094022 03 and 2013ZX09103001-008).